Lawmakers’ calls for tougher regulation of compounding pharmacies are nothing new. Over decades, there have been a series of attempts at the federal level to rein in a business that has largely evaded the kind of stringent oversight established drug makers face.
Federal regulators have long been flummoxed by the growth of the compounding pharmacy industry, which is made up of thousands of small outfits that specially mix medicines for patients, along with an expanding class of industrial-scale manufacturers that ship products to health care providers nationally.
Comments
"But the legislation never came to a vote because of opposition from compounding pharmacy lobbyists and other trade groups that argued such a law would prevent the speedy delivery of medications not available at traditional pharmacies."
>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>
Correction, Chelsea: -- the legislation never came to a vote because Congress did not do the right thing. Lobbyists don't control what happens in Congress, even if Congress wants to blame them for what they do or do not do (if they did, then lobbying would have to be made illegal). The menningitis outbreak and the resulting deaths are the result of inadequate regulation, and the inadequate regulation can be laid at Congress's doorstep.
Is there any headline that Markey won't jump on?